Biogen Inc (BIIB)

291.71
-1.49(-0.51%)
After Hours
290.76
-0.95(-0.33%)
- Real-time Data
  • Volume:
    813,435
  • Bid/Ask:
    290.75/293.31
  • Day's Range:
    289.00 - 293.47

BIIB Overview

Prev. Close
293.2
Day's Range
289-293.47
Revenue
11.7B
Open
289.86
52 wk Range
223.25-468.2
EPS
12.47
Volume
813,435
Market Cap
43.47B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,134,623
P/E Ratio
23.40
Beta
0.45
1-Year Change
6.74%
Shares Outstanding
149,033,443
Next Earnings Date
25 Oct 2021
What is your sentiment on Biogen Inc?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Biogen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellBuy
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellNeutral
SummaryStrong BuyBuyStrong SellStrong SellNeutral

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.